The Bombay High Court has restrained Gleck Pharma from using XIGAMET for its diabetes product, finding it deceptively similar to Glenmark’s ZITA-MET. This decision highlights the Court’s heightened scrutiny in pharmaceutical trademark cases to prevent consumer confusion and associated health risks.
Read more about Diabetic Product XigaMet Loses to ZitaMet Under Heightened Pharma Trademark ScrutinyTag: Glenmark Pharmaceuticals
Drug Humira turns Rheumatic for Abbott Biotechnology
The Indian Patent Office set aside Abbott Biotechnology’s Humira patent after Glenmark’s pre-grant opposition, citing lack of inventive step and insufficient disclosure. This legal dispute underscores ongoing challenges to Humira patents both in India and globally.
Read more about Drug Humira turns Rheumatic for Abbott Biotechnology